Vice Provost and Dean of Research
Showing 1,881-1,890 of 2,457 Results
-
Noah Rosenberg
Stanford Professor of Population Genetics and Society
Current Research and Scholarly InterestsHuman evolutionary genetics, mathematical models in evolution and genetics, mathematical phylogenetics, statistical and computational genetics, theoretical population genetics
-
David Rosenthal
Professor of Pediatrics (Pediatric Cardiology)
Current Research and Scholarly InterestsResearch interests include the study of Heart Failure, Cardiomyopathy and ventricular dysfunction in children, from a clinical perspective. Investigations include clinical trials of medications, cardiac resynchronization, and mechanical circulatory support.
-
Sin Rosenthal
Financial Analyst, Office of Technology Licensing (OTL)
BioSin is responsible for royalty sharing agreements, equity related tasks, billing licensees, aging reports, progress and earned royalty reports, royalty distribution, and special projects that are assigned to her.
-
Jason B. Ross, MD, PhD
Assistant Professor of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsMy laboratory studies studying normal, dysfunctional, and malignant stem cells in the context of aging, cancer, and cancer therapies.
-
Maya Rossin-Slater
Associate Professor of Health Policy, Senior Fellow at the Stanford Institute for Economic Policy Research and Associate Professor, by courtesy, of Economics
Current Research and Scholarly InterestsHealth and public economics; public policy; families; health disparities
-
Gregory Rosston
Gordon Cain Senior Fellow at the Stanford Institute for Economic Policy Research
BioGreg Rosston is Director of the Public Policy program at Stanford University, the Gordon Cain Senior Fellow at the Stanford Institute for Economic Policy Research, and Professor of Economics (by courtesy). He teaches Economics and Public Policy courses on competition policy and strategy, economic policy analysis, and writing and rhetoric.
Dr. Rosston served as Deputy Chief Economist at the Federal Communications Commission working on the implementation of the Telecommunications Act of 1996 and the design and implementation of the first ever spectrum auctions in the United States. In 2011, he was Senior Economist for Transactions for the Federal Communications Commission for the proposed AT&T – T-Mobile transaction. He served as a member and co-chair of the Department of Commerce Spectrum Management Advisory Committee.
Dr. Rosston received his Ph.D. in Economics from Stanford University and his A.B. with Honors from the University of California at Berkeley. Dr. Rosston has written extensively on the application of economics to telecommunications and competition issues. He has advised companies and governments regarding auctions and served as a consultant to various organizations including the World Bank and the Federal Communications Commission, and as a board member and advisor to high technology, financial, and startup companies. He serves as Vice Chair of the Board of the Stanford Federal Credit Union, as a Board member of the Nepal Youth Foundation and as an Advisory Board member of Sustainable Conservation and the Technology Policy Institute. -
Stephen J. Roth
Professor of Pediatrics (Cardiology), Emeritus
Current Research and Scholarly InterestsRandomized Therapeutic Trials in Pediatric Heart Disease, NIH/U01 GrantNo. HL68285 2001-2006.
Heparin and the Reduction of Thrombosis (HART) Study. Pediatric Health Research Fund Award, Stanford Univ Sch of Medicine, 2005-2006.
A Pilot Trial fo B-type Natriuretic Peptide for Promotion of Urine Output in Diuretic-Resistant Infants Following Cardiovascular Surgery.Pediatric Health Research Fund Award, Stanford Univ Sch of Medicine, 2005-2006. -
Theodore Roth
Assistant Professor of Pathology
Current Research and Scholarly InterestsThe Roth Lab develops, applies, and translates scalable genetic manipulation technologies in primary human cells and complex in vivo tissue environments. Working with students, trainees, and staff with backgrounds across bioengineering, genetics, immunology, oncology, and pathology, the lab has developed CRISPR-All, a unified genetic perturbation language able to arbitrarily and combinatorially examine genetic perturbations across perturbation type and scale in primary human cells. Ongoing applications of CRISPR-All in the lab have revealed surprising capacities to synthetically engineer human cells beyond evolved cellular states. These new capacities to perturb human cell’s genetics beyond their evolved functionality drives ongoing work to understand the biology and therapeutic potential of synthetic cell state engineering - in essence learning how to build new human genes tailor made for a specific cell and specific environment to drive previously inaccessible therapeutic cellular functions.
